← Leaderboards
G Greg Wang
Duke University
$11,565,583
Attributed
$18,443,943
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.8M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,443,943 · 9
By mechanism
R01$17,443,680 · 7
R00$724,590 · 1
K99$275,673 · 1
Top collaborators
- Jian Jin19 shared
- Douglas H. Phanstiel5 shared
- Ling Cai1 shared
Most similar at Duke University
Same institution · by research overlap
- Jian Jin$14,335,932
- Joseph A. Goldman$173,914
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroNovel Therapeutic InterventionBindingMalignant NeoplasmsCellsLeukemiaMediatingTumorTumorigenesisGenesIn VivoTechnologyComplexGrowthOncogenicHistonesInnovationPathway InteractionsChromatinCancer CellHistone MethyltransferaseProgramsGene ExpressionLysine
Grant awards (41)
Understanding and targeting epigentic regulation of immune evasion in prostate cancer$2,895,540
R01 · FY2025 · CA
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias$654,354
R01 · FY2025 · CA
Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in caner$640,960
R01 · FY2025 · CA · contact PI
The role for phase separation in oncogenesis and aberrant chromatin looping formation$577,785
R01 · FY2025 · CA · contact PI
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias$621,637
R01 · FY2024 · CA
Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in caner$608,912
R01 · FY2024 · CA · contact PI
The role for phase separation in oncogenesis and aberrant chromatin looping formation$548,895
R01 · FY2024 · CA · contact PI
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias$92,168
R01 · FY2024 · CA
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias$641,266
R01 · FY2023 · CA
The role for phase separation in oncogenesis and aberrant chromatin looping formation$572,770
R01 · FY2023 · CA · contact PI
Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in cancer$479,306
R01 · FY2023 · CA · contact PI
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias$422,496
R01 · FY2023 · CA
Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in caner$230,678
R01 · FY2023 · CA · contact PI
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias$97,018
R01 · FY2023 · CA
The role for phase separation in oncogenesis and aberrant chromatin looping formation$1
R01 · FY2023 · CA · contact PI
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias$671,604
R01 · FY2022 · CA
Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in cancer$643,960
R01 · FY2022 · CA · contact PI
The role for phase separation in oncogenesis and aberrant chromatin looping formation$577,786
R01 · FY2022 · CA · contact PI
Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias$532,355
R01 · FY2021 · CA
Cancer Epigenetics: A novel PRC2 Dysregulation Mechanism in Multiple Myeloma$390,643
R01 · FY2021 · CA · contact PI
Determining the Role of DNA Methylation Deregulation in Oncogenesis$348,584
R01 · FY2021 · CA · contact PI
Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias$89,033
R01 · FY2021 · CA
Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias$27,371
R01 · FY2021 · CA
Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias$532,355
R01 · FY2020 · CA
Cancer Epigenetics: A novel PRC2 Dysregulation Mechanism in Multiple Myeloma$390,643
R01 · FY2020 · CA · contact PI
Determining the Role of DNA Methylation Deregulation in Oncogenesis$348,584
R01 · FY2020 · CA · contact PI
Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias$516,385
R01 · FY2019 · CA
Cancer Epigenetics: A novel PRC2 Dysregulation Mechanism in Multiple Myeloma$378,924
R01 · FY2019 · CA · contact PI
Determining the Role of DNA Methylation Deregulation in Oncogenesis$338,128
R01 · FY2019 · CA · contact PI
Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias$532,355
R01 · FY2018 · CA
Cancer Epigenetics: A novel PRC2 Dysregulation Mechanism in Multiple Myeloma$390,643
R01 · FY2018 · CA · contact PI
Determining the Role of DNA Methylation Deregulation in Oncogenesis$348,584
R01 · FY2018 · CA · contact PI
Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias$549,730
R01 · FY2017 · CA
Cancer Epigenetics: A novel PRC2 Dysregulation Mechanism in Multiple Myeloma$403,643
R01 · FY2017 · CA · contact PI
Determining the Role of DNA Methylation Deregulation in Oncogenesis$348,584
R01 · FY2017 · CA · contact PI
Cancer epigenetics: Understanding histone methylation in leukemia stem cells$241,530
R00 · FY2014 · CA · contact PI
Cancer epigenetics: Understanding histone methylation in leukemia stem cells$234,060
R00 · FY2013 · CA · contact PI
Cancer epigenetics: Understanding histone methylation in leukemia stem cells$249,000
R00 · FY2012 · CA · contact PI
Cancer epigenetics: Understanding histone methylation in leukemia stem cells$104,253
K99 · FY2011 · CA · contact PI
Cancer epigenetics: Understanding histone methylation in leukemia stem cells$35,274
K99 · FY2011 · CA · contact PI
Cancer epigenetics: Understanding histone methylation in leukemia stem cells$136,146
K99 · FY2010 · CA · contact PI